Skip to main content

Table 1 Baseline clinical characteristics of the patients in the disease progression group and non-recurrence/non-disease progression group

From: Baseline MRI-based radiomics model assisted predicting disease progression in nasopharyngeal carcinoma patients with complete response after treatment

Clinical characteristic Disease progression group (n = 76) Non-disease progression group
(n = 95)
P value
Age (mean ± SD, years) 46.0 ± 12.4 42.0 ± 12.7 0.04*
Gender 0.01*
 Male 66 67  
 Female 10 28  
Histology 0.07
 Differentiated Non-keratinising 45 43  
 Undifferentiated
Non-keratinising
31 52  
T stage 0.79
 T1 8 15  
 T2 14 17  
 T3 31 35  
 T4 23 28  
N stage 0.22
 N0 3 9  
 N1 21 34  
 N2 36 39  
 N3 16 13  
Overall stage 0.52
 I 0 1  
 II 8 11  
 III 28 41  
 IV 40 42  
Treatment 0.50
 A 12 10  
 B 39 45  
 C 3 7  
 D 22 33  
EA-IgA
 positive 23 30 0.85
 negative 53 65  
VCA-IgA
 positive 53 57 0.19
 negative 23 38  
Smoking 0.02*
 Yes 44 38  
 No 32 57  
  1. Treatment: A-Radiotherapy only, B-Chemotherapy + Radiotherapy, C-Targeted therapy + Radiotherapy, D-Concurrent Chemoradiotherapy + Targeted Therapy, E-Chemotherapy + Targeted Therapy; * indicates statistical significant difference